Navigation Links
Zyflamend inhibits 78 percent of prostate cancer cells

An article published in the October issue of the journal Nutrition and Cancer says that Zyflamend, an herbal extract from olive oil could end the search for a drug to beat prostate cancer.//

It was found that this element caused the prostate cancer cells to commit "suicide." The researchers report that the drug had the ability to inhibit 78 percent of the cancer cell growth plus it also caused "apoptosis". This is the natural process by which a cell dies. Cell death in this way is a physiological process and Zyflamend's ability to trigger this action bodes well for the future, according to the lead researcher in the study, Dr. Debra L. Bemis of Columbia University College of Physicians and Surgeons, New York. "Together, these results suggest that Zyflamend might have some chemopreventive utility against prostate cancer in men," she said.

It was also found that Zyflamend had both COX-1 and COX-2 inhibitory effects on the cancer cells and was shown to decrease the activity of both these enzymes in a dramatic manner in the laboratory setting. "We are currently conducting a Phase I clinical trial for men with a pre-cancerous lesion of the prostate -- prostatic intraepithelial neoplasia -- to gain some information as to Zyflamend's potential to prevent or slow... progression to prostate cancer," Dr. Bemis concluded.

The COX inhibitors are known to have some effect on prostate cancer cells, but are contraindicated in heart disease since they have adverse impact on the heart. Zyflamend was seen to have the similar chemical structure as that of Aspirin.

Related medicine news :

1. Garlic inhibits fungal growth and protects food
2. Pharmacia may take 51.5 percent Abbott stake
3. NHS Forced to Borrow Money at Rates of 10 percent
4. Thirty percent of nurses distressed with verbal and physical abuse
5. 17 percent rise in childhood cancer cases due to modern lifestyles
6. Supercentenarian Center to study longevity
7. Better prostate cancer detection
8. Protective effects of tomatoes in prostate cancer
9. Early detection of prostate cancer
10. Fingerprinting prostate cancer
11. No link between blood groups and prostate cancer
Post Your Comments:

(Date:6/25/2016)... Long Beach, CA (PRWEB) , ... June 25, 2016 , ... ... from UCLA with Magna Cum Laude and his M.D from the David Geffen School ... San Diego and returned to Los Angeles to complete his fellowship in hematology/oncology at ...
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of ... recognition of their exemplary accomplishments in worksite health promotion. , The Wellness at Work ... Symposium at the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses ...
(Date:6/24/2016)... ... 2016 , ... A recent article published June 14 on E ... goes on to state that individuals are now more comfortable seeking to undergo not ... as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians ...
(Date:6/24/2016)... Marne, Michigan (PRWEB) , ... June 24, 2016 , ... ... awareness about the dangers associated with chronic pain and the benefits of holistic treatments, ... for individuals who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) ...
(Date:6/24/2016)... ... 24, 2016 , ... The Pulmonary Hypertension Association (PHA) learned ... receive two significant new grants to support its work to advance research and ... by recognizing patients, medical professionals and scientists for their work in fighting pulmonary ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 2016  Arkis BioSciences, a leading innovator in ... durable cerebrospinal fluid treatments, today announced it has ... is led by Innova Memphis, followed by Angel ... investors.  Arkis, new financing will accelerate the commercialization ... release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... , June 23, 2016 Research ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, ... (Oral, Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is ... a CAGR of 6.1% in the forecast period 2016 ...
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
Breaking Medicine Technology: